UNITED STATES

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TYenx9TwEQ9/G0gllwpB4IVhTdb2iNZAj1wr7Vlucic0/orA8avihU/9SwLkqBmr U3ypozpPUoD62UQA2kT9rw== 0000950005-07-000010.txt : 20070116 0000950005-07-000010.hdr.sgml : 20070115 20070116122303 ACCESSION NUMBER: 0000950005-07-000010 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20070116 DATE AS OF CHANGE: 20070116 GROUP MEMBERS: ALIX MARDUEL GROUP MEMBERS: ALTA BIOPHARMA MANAGEMENT II, LLC GROUP MEMBERS: ALTA BIOPHARMA PARTNERS II, L.P. GROUP MEMBERS: ALTA EMBARCADERO BIOPHARMA PARTNERS II, LLC GROUP MEMBERS: ALTA PARTNERS II, INC. GROUP MEMBERS: FARAH CHAMPSI GROUP MEMBERS: JEAN DELEAGE SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC CENTRAL INDEX KEY: 0001088856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770487658 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-80200 FILM NUMBER: 07531222 BUSINESS ADDRESS: STREET 1: 275 MIDDLEFIELD ROAD STREET 2: SUITE A CITY: MENLO PARK STATE: CA ZIP: 94025 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ALTA PARTNERS II INC CENTRAL INDEX KEY: 0001276361 IRS NUMBER: 943382738 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: ONE EMBARCADERO CENTER STREET 2: SUITE 3700 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 BUSINESS PHONE: 4153624022 MAIL ADDRESS: STREET 1: ONE EMBARCADERO CENTER STREET 2: SUITE 3700 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 SC 13G/A 1 f2000913g.htm SCHEDULE 13G/A #2 UNITED STATES

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

(Amendment No. _2_)*

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Corcept Therapeutics Incorporated

(Name of Issuer)

Common Stock

(Title of Class of Securities)

218352102

(CUSIP Number)

December 31, 2006

(Date of Event That Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 218352102

Page 2 of 13 Pages

(1) Names of Reporting Persons. SS or I.R.S. Identification Nos. of Above Persons

Alta Partners II, Inc.

(2) Check The Appropriate Box If A Member Of A Group

(a)

(b)

(3)

SEC Use Only

(4)

Citizenship or Place of Organization

California &nbs p;

Please see Attachment A

Number Of Shares

(5)

Sole Voting Power

-0-

Beneficially Owned

By Each Reporting

(6)

Shared Voting Power

1,698,274

Person With

Please see Attachment A

(7)

Sole Dispositive Power

-0-

(8)

Shared Dispositive Power 1,698,274

Please see Attachment A

(9)

Aggregate Amount Beneficially Owned By Each Reporting Person

1,698,274 Please see Attachment A

(10)

Check If The Aggregate Amount In Row (11) Excludes Certain Shares*

(11)

Percent Of Class Represented By Amount In Row (11)

6.60% Please see Attachment A

(12)

Type Of Reporting Person

IA &nb sp;

*SEE INSTRUCTION BEFORE FILLING OUT!

CUSIP No. 218352102

Page 3 of 13 Pages

(1) Names of Reporting Persons. SS or I.R.S. Identification Nos. of Above Persons

Alta BioPharma Partners II, L.P.

(2) Check The Appropriate Box If A Member Of A Group

(a)

(b)

(3)

SEC Use Only

(4)

Citizenship or Place of Organization

Delaware

Please see Attachment A

Number Of Shares

(5)

Sole Voting Power

-0-

Beneficially Owned

By Each Reporting

(6)

Shared Voting Power

1,698,274

Person With

Please see Attachment A

(7)

Sole Dispositive Power

-0-

(8)

Shared Dispositive Power 1,698,274

Please see Attachment A

&nbs p;

(9)

Aggregate Amount Beneficially Owned By Each Reporting Person

1,698,274 Please see Attachment A

(10)

Check If The Aggregate Amount In Row (11) Excludes Certain Shares*

(11)

Percent Of Class Represented By Amount In Row (11)

6.60% Please see Attachment A

(12)

Type Of Reporting Person

PN &nb sp;

CUSIP No. 218352102

Page 4 of 13 Pages

(1) Names of Reporting Persons. SS or I.R.S. Identification Nos. of Above Persons

Alta BioPharma Management II, LLC

(2) Check The Appropriate Box If A Member Of A Group

(a)

(b)

(3)

SEC Use Only

(4)

Citizenship or Place of Organization

Delaware

Please see Attachment A

Number Of Shares

(5)

Sole Voting Power

-0-

Beneficially Owned

By Each Reporting

(6)

Shared Voting Power

1,698,274

Person With

Please see Attachment A

(7)

Sole Dispositive Power

-0-

(8)

Shared Dispositive Power 1,698,274

Please see Attachment A

&n bsp;

(9)

Aggregate Amount Beneficially Owned By Each Reporting Person

1,698,274 Please see Attachment A

(10)

Check If The Aggregate Amount In Row (11) Excludes Certain Shares*

(11)

Percent Of Class Represented By Amount In Row (11)

6.60% Please see Attachment A

(12)

Type Of Reporting Person

CO &nb sp;

CUSIP No. 218352102

Page 5 of 13 Pages

(1) Names of Reporting Persons. SS or I.R.S. Identification Nos. of Above Persons

Alta Embarcadero BioPharma Partners II, LLC

(2) Check The Appropriate Box If A Member Of A Group

(a)

(b)

(3)

SEC Use Only

(4)

Citizenship or Place of Organization

Delaware

Please see Attachment A

Number Of Shares

(5)

Sole Voting Power

-0-

Beneficially Owned

By Each Reporting

(6)

Shared Voting Power

1,698,274

Person With

Please see Attachment A

(7)

Sole Dispositive Power

-0-

(8)

Shared Dispositive Power 1,698,274

Please see Attachment A

(9)

Aggregate Amount Beneficially Owned By Each Reporting Person

1,698,274 Please see Attachment A

(10)

Check If The Aggregate Amount In Row (11) Excludes Certain Shares*

(11)

Percent Of Class Represented By Amount In Row (11)

6.60% Please see Attachment A

(12)

Type Of Reporting Person

CO &nb sp;

CUSIP No. 218352102

Page 6 of 13 Pages

(1) Names of Reporting Persons. SS or I.R.S. Identification Nos. of Above Persons

Farah Champsi

(2) Check The Appropriate Box If A Member Of A Group

(a)

(b)

(3)

SEC Use Only

(4)

Citizenship or Place of Organization

United States & nbsp;

Please see Attachment A

Number Of Shares

(5)

Sole Voting Power

-0-

Beneficially Owned

By Each Reporting

(6)

Shared Voting Power

1,698,274

Person With

Please see Attachment A

(7)

Sole Dispositive Power

-0-

(8)

Shared Dispositive Power 1,698,274

Please see Attachment A

(9)

Aggregate Amount Beneficially Owned By Each Reporting Person

1,698,274 Please see Attachment A

(10)

Check If The Aggregate Amount In Row (11) Excludes Certain Shares*

(11)

Percent Of Class Represented By Amount In Row (11)

6.60% Please see Attachment A

(12)

Type Of Reporting Person

IN &nb sp;

*SEE INSTRUCTION BEFORE FILLING OUT!

CUSIP No. 218352102

Page 7 of 13 Pages

(1) Names of Reporting Persons. SS or I.R.S. Identification Nos. of Above Persons

Jean Deleage &n bsp;

(2) Check The Appropriate Box If A Member Of A Group

(a)

(b)

(3)

SEC Use Only

(4)

Citizenship or Place of Organization

United States & nbsp;

Please see Attachment A

Number Of Shares

(5)

Sole Voting Power

-0-

Beneficially Owned

By Each Reporting

(6)

Shared Voting Power

1,698,274

Person With

Please see Attachment A

(7)

Sole Dispositive Power

-0-

(8)

Shared Dispositive Power 1,698,274

Please see Attachment A

(9)

Aggregate Amount Beneficially Owned By Each Reporting Person

1,698,274 Please see Attachment A

(10)

Check If The Aggregate Amount In Row (11) Excludes Certain Shares*

(11)

Percent Of Class Represented By Amount In Row (11)

6.60% Please see Attachment A

(12)

Type Of Reporting Person

IN &nb sp;

*SEE INSTRUCTION BEFORE FILLING OUT!

CUSIP No. 218352102

Page 8 of 13 Pages

(1) Names of Reporting Persons. SS or I.R.S. Identification Nos. of Above Persons

Alix Marduel &n bsp;

(2) Check The Appropriate Box If A Member Of A Group

(a)

(b)

(3)

SEC Use Only

(4)

Citizenship or Place of Organization

United States & nbsp;

Please see Attachment A

Number Of Shares

(5)

Sole Voting Power

-0-

Beneficially Owned

By Each Reporting

(6)

Shared Voting Power

1,698,274

Person With

Please see Attachment A

(7)

Sole Dispositive Power

-0-

(8)

Shared Dispositive Power 1,698,274

Please see Attachment A

(9)

Aggregate Amount Beneficially Owned By Each Reporting Person

1,698,274 Please see Attachment A

(10)

Check If The Aggregate Amount In Row (11) Excludes Certain Shares*

(11)

Percent Of Class Represented By Amount In Row (11)

6.60% Please see Attachment A

(12)

Type Of Reporting Person

IN &nb sp;

*SEE INSTRUCTION BEFORE FILLING OUT!

Item 1.

(a)

Name of Issuer: Corcept Therapeutics Incorporated. (“Issuer”)

(b)

Address of Issuer’s Principal Executive Offices:

149 Commonwealth Drive

Menlo Park, CA 94025

Item 2.

(a)

Name of Person Filing:

Alta Partners II, Inc. (“AP II”)

Alta BioPharma Partners II, L.P. (“ABP II”)

Alta BioPharma Management II, LLC (“ABM II”)

Alta Embarcadero BioPharma Partners II, LLC (“AEBP II”)

Farah Champsi (“FC”)

Jean Deleage (“JD”)

Alix Marduel (“AM”)

(b)

Address of Principal Business Office:

One Embarcadero Center, Suite 4050

San Francisco, CA 94111

(c)

Citizenship/Place of Organization:

Entities:

AP II

California

ABP II

Delaware

ABM II

Delaware

AEBP II

California

Individuals:

United States

(d)

Title of Class of Securities:

Common Stock

(e)

CUSIP Number: 218352102

Item 3.

Not applicable.

Item 4

Ownership.

Please see Attachment A


		AP II	ABP II	ABM II	AEBP II	FC	JD	AM
(a)	Beneficial Ownership	1,698,274	1,698,274	1,698,274	1,698,274	1,698,274	1,698,274	1,698,274
(b)	Percentage of Class	6.60%	6.60%	6.60%	6.60%	6.60%	6.60%	6.60%
(c)	Sole Voting Power	-0-	-0-	-0-	-0-	-0-	-0-	-0-
	Shared Voting Power	1,698,274	1,698,274	1,698,274	1,698,274	1,698,274	1,698,274	1,698,274
	Sole Dispositive Power	-0-	-0-	-0-	-0-	-0-	-0-	-0-
	Shared Dispositive Power	1,698,274	1,698,274	1,698,274	1,698,274	1,698,274	1,698,274	1,698,274

Item 5.

Ownership of Five Percent or Less of a Class

Not Applicable.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8.

Identification and Classification of Members of the Group

No reporting person is a member of a group as defined in Section 240.13d-1(b)(1)(ii)(H) of the Act.

Item 9.

Notice of Dissolution of Group

Not applicable.

Item 10.

Certification

By signing below we certify that, to the best of our knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

EXHIBITS

Joint Filing Statement

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date:

January 12, 2007

ALTA PARTNERS II, INC.

By: /s/ Jean Deleage

Jean Deleage, President

ALTA BIOPHARMA PARTNERS II, L.P.

ALTA BIOPHARMA MANAGEMENT II, LLC

By: Alta BioPharma Management II, LLC

By: /s/ Farah Champsi

Farah Champsi, Managing Director

ALTA EMBARCADERO BIOPHARMA PARTNERS II, LLC

By: /s/ Farah Champsi

/s/ Alix Marduel

Farah Champsi, Manager

Alix Marduel

/s/ Jean Deleage

/s/ Farah Champsi

Jean Deleage

Farah Champsi

EXHIBIT A

AGREEMENT OF JOINT FILING

Date:

January 12, 2007

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ALTA PARTNERS II, INC.

By: /s/ Jean Deleage

Jean Deleage, President

ALTA BIOPHARMA PARTNERS II, L.P.

ALTA BIOPHARMA MANAGEMENT II, LLC

By: Alta BioPharma Management II, LLC

By: /s/ Farah Champsi

Farah Champsi, Managing Director

ALTA EMBARCADERO BIOPHARMA PARTNERS II, LLC

By: /s/ Farah Champsi

/s/ Alix Marduel

Farah Champsi, Manager

Alix Marduel

/s/ Jean Deleage

/s/ Farah Champsi

Jean Deleage

Farah Champsi

Attachment A

Alta Partners II, Inc. provides investment advisory services to several venture capital funds including Alta BioPharma Partners II, L.P. and Alta Embarcadero BioPharma Partners II, LLC. Alta BioPharma Partners II, L.P. beneficially owns 1,632,012 shares of Common Stock and Alta Embarcadero BioPharma Partners II, LLC beneficially owns 66,262 shares Common Stock. The managing directors of Alta BioPharma Partners II, L.P. and managers of Alta Embarcadero BioPharma Partners II, LLC exercise sole voting and investment power in respect to the shares owned by such funds.

Certain principals of Alta Partners II, Inc. are managing directors of Alta BioPharma Management II, LLC (which is the general partner of Alta BioPharma Partners II, L.P.), and managers of Alta Embarcadero BioPharma Partners II, LLC. As managing directors and managers of such entities, they may be deemed to share voting and investment powers over the shares beneficially held by such funds. The principals of Alta Partners II, Inc. disclaim beneficial ownership of all such shares held by the foregoing funds, except to the extent of their proportionate pecuniary interests therein.

Dr. Alix Marduel, Director, is a managing director of Alta BioPharma Management II, LLC (which is the general partner of Alta BioPharma Partners II, L.P.) and a manager of Alta Embarcadero BioPharma Partners II, LLC. Thus she currently shares voting and dispositive powers over the 1,632,012 shares of Common Stock beneficially owned by Alta BioPharma Partners II, L.P. and the 66,262 shares of Common Stock beneficially owned by Alta Embarcadero BioPharma Partners II, LLC. She disclaims beneficial ownership of all such shares held by the foregoing funds except to the extent of her proportionate pecuniary interests therein.

Mr. Jean Deleage is a managing director of Alta BioPharma Management II, LLC (which is the general partner of Alta BioPharma Partners II, L.P.), and a manager of Alta Embarcadero BioPharma Partners II, LLC. Thus he currently shares voting and dispositive powers over the 1,632,012 shares of Common Stock beneficially owned by Alta BioPharma Partners II, L.P., and the 66,262 shares of Common Stock beneficially owned by Alta Embarcadero BioPharma Partners II, LLC. He disclaims beneficial ownership of all such shares held by the foregoing funds except to the extent of his proportionate pecuniary interests therein.

Ms. Farah Champsi is a managing director of Alta BioPharma Management II, LLC (which is the general partner of Alta BioPharma Partners II, L.P.) and a manager of Alta Embarcadero BioPharma Partners II, LLC. Thus she currently shares voting and dispositive powers over the 1,632,012 shares of Common Stock beneficially owned by Alta BioPharma Partners II, L.P. and the 66,262 shares of Common Stock beneficially owned by Alta Embarcadero BioPharma Partners II, LLC. She disclaims beneficial ownership of all such shares held by the foregoing funds except to the extent of her proportionate pecuniary interests therein.

Alta Partners II, Inc. is a venture capital firm with an office in San Francisco. Alta Partners II, Inc. is a California Corporation. Alta BioPharma Partners II, L.P. is a Delaware Limited Partnership, and Alta Embarcadero BioPharma Partners II, LLC is a California Limited Liability Company.

-----END PRIVACY-ENHANCED MESSAGE-----